Physician profile
Mark L Tanner
NPI 1033122445
$94,311.32
in general payments reported to CMS, 2019-2025
62 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,374 · 2020: $7,979 · 2021: $24K · 2022: $25K · 2023: $14K · 2024: $5,105 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,183 · Consulting Fee: $5,320 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,346 · Travel and Lodging: $224 · Education: $72.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,054.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,183.00 |
| Consulting Fee | $5,320.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,345.91 |
| Travel and Lodging | $224.17 |
| Education | $72.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $53,425.02 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $7,767.27 | 2019-2025 | Yeztugo, Biktarvy |
| Napo Pharmaceuticals INC | $6,970.81 | 2019-2025 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $3,081.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $3,029.53 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $2,956.95 | 2019-2025 | Wegovy, Ozempic |
| Janssen Products, LP | $1,278.58 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $1,266.44 | 2019-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Abbvie INC. | $1,248.25 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $1,240.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Biotech, INC. | $871.95 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $871.93 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Amarin Pharma, INC. | $801.38 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $687.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $619.90 | 2019-2025 | Xifaxan, Trulance |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $522.50 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $500.93 | 2019-2025 | |
| Aytu Biopharma, INC. | $488.02 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $453.72 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $444.28 | 2020-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $438.54 | 2019-2020 | |
| Abbott Laboratories | $436.92 | 2019-2025 | Freestyle Libre 3 |
| Emd Serono, INC. | $407.66 | 2019-2025 | Serostim |
| Axsome Therapeutics, INC. | $340.39 | 2024-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $308.66 | 2020-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $286.60 | 2019-2024 | Spravato |
| Bausch Health US, LLC | $281.37 | 2021-2025 | Aplenzin, Wellbutrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.20 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $247.92 | 2020-2023 | Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $237.70 | 2021-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $237.03 | 2019-2024 | Livalo, Seglentis |
| Tris Pharma INC | $224.43 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Radius Health, INC. | $210.76 | 2024-2025 | Tymlos |
| Tolmar, INC. | $204.90 | 2023-2025 | Jatenzo |
| Vanda Pharmaceuticals INC. | $191.71 | 2020-2024 | Fanapt |
| Eisai INC. | $139.72 | 2020-2021 | |
| Mannkind Corporation | $125.35 | 2019 | |
| Metuchen Pharmaceuticals | $125.00 | 2019 | |
| Currax Pharmaceuticals LLC | $112.06 | 2022-2023 | Contrave, Nexlizet, Nexletol |
| Paratek Pharmaceuticals, INC. | $98.92 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $95.39 | 2021-2023 | Natesto |
| Verity Pharmaceuticals INC. | $92.86 | 2024-2025 | Tlando |
| Exact Sciences Corporation | $76.98 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $71.90 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $65.97 | 2020-2022 | |
| Astellas Pharma US INC | $58.69 | 2024-2025 | Veozah |
| Inspire Medical Systems, INC. | $49.93 | 2024 | Inspire |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.80 | 2022 | |
| Optinose US, INC. | $36.96 | 2021-2025 | |
| Medline Industries LP | $36.22 | 2020 | |
| Idorsia Pharmaceuticals US INC | $32.29 | 2023 | Quviviq |
| Clarus Therapeutics INC. | $31.77 | 2021 | |
| Dexcom, INC. | $27.00 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $23.25 | 2024 | Xyosted |
| Alkermes, INC. | $22.57 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.33 | 2023 | Edarbi |
| Ascendis Pharma Endocrinology INC | $18.23 | 2025 | Yorvipath |
| E.R. Squibb & Sons, L.L.C. | $17.92 | 2020 | |
| Ibsa Pharma INC. | $16.73 | 2024 | Tirosint, Licart |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Zyla Life Sciences, INC. | $11.95 | 2019 | |
| Janssen Scientific Affairs, LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.